Sonpavde GP, Sternberg CN, Loriot Y, Marabelle A, et al. Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. Eur J Cancer 2022;163:55-65.
PMID: 35042068